The XLIV Paraguay Sessions Have Started – Day 1

The day is finally here. The XLIV SOLACI Sessions (15th Southern Cone Region) began in Paraguay, with participants attending both in person and virtually, and the participation of prestigious interventional cardiologists from Paraguay and Latin America.

The event is a scientific success, with over 200 registrations for in-person attendance and 700+ people connecting via Zoom.

 

The first day of activities began with the opening ceremony, where the President of the Paraguayan Society of Cardiology and Cardiovascular Surgery (SPCyCC), Dr. Alberto Marecos Baruja, and the SOLACI Sessions Director, Dr. Gustavo Vignolo, welcomed the attendees to what would be an intense day of theoretical and practical learning in cardiovascular interventionism.

The morning modules focused on Chronic Ischemic Heart Disease and Non-ST Elevation Acute Coronary Syndromes, with important presentations on chronic coronary syndromes (CCS), pharmacological strategies, revascularization in CCS, acute coronary syndromes, multi-vessel disease, and acute coronary syndromes in young women (among other topics).

Afterwards, the Director of the SolSOLACI Program, Dr. Marcelo Halac, opened the session on charitable pediatric cases and presented the main achievements of a chapter that has already been involved in over 70 charitable cases throughout the continent. In this sense, he explained that the main objective of the program is facilitating access to cardiovascular procedures for low-income patients who lack medical coverage in Latin American and Caribbean countries.

In the afternoon, there were sessions on antiplatelet and anticoagulation therapies (with interesting presentations on double antiplatelet therapy, post-angioplasty anticoagulation, post-TAVR antithrombotic treatment, bleeding complications, and more), and on Acute Coronary Syndromes with ST Elevation (where relevant topics such as infarct codes, pharmaco-invasive strategies, late acute infarction, and clinical cases were discussed). 

We hope you will join us to continue enjoying an unmissable event for all interventional cardiologists from Paraguay and the region.

« of 2 »

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Uruguay Sessions 2025 | Young Interventional Cardiologists Contest

Call for Case Submission LI SOLACI Regional Sessions – 16° Southern Cone  It is with great pleasure that we hereby invite all young Latin American cardiologists...

Watch Angioplasty Techniques for Bifurcations Again From a Completely Different Perspective.

You can now watch on our YouTube channel the event we held in collaboration with Medtronic, titled: "Visualizations of Different PCI Techniques for Bifurcations...

2025 SOLACI Research Grant

By initiative of the board of directors (together with the research department), SOLACI is launching a research grant aimed at improving knowledge and access...

New Virtual Event from CHIP LATAM SOLACI: Mexico Chapter

The Latin American Society of Interventional Cardiology invites you to participate in a new educational activity organized by the Department of Complex Percutaneous Coronary...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...